Merus completed its rollout of Phase 2 head and neck cancer data on Thursday, touting overall survival results that at least ...

GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary ...

Jazz's Zepzelca + Roche's Tecentriq shows 27% reduced death risk & improved survival in lung cancer trial; FDA application ...

The House of Representatives on Thursday passed President Donald Trump’s tax cut package, with steep Medicaid cuts, PBM ...

FDA Commissioner Marty Makary defended thousands of staff cuts during his first congressional hearing since taking office, ...

Hinge Health shares jumped 23% in its first day trading as a public company, setting the tone for digital health after a ...

Cigna on Wednesday said it negotiated with Novo Nordisk and Eli Lilly to secure deeper GLP-1 drug discounts for employers ...

The White House released its first MAHA Commission report, detailing some of the Trump administration’s top priorities for ...

Venrock's Healthcare Prognosis survey shows 71% favor AI integration in existing companies over new AI firms, with mixed ...

After a median 34.2 months of follow-up, patients taking Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex survived for a median of 34 months, compared to 27 months for those ...

Sanofi will acquire Vigil for its oral small molecule TREM2 project, dubbed VG-3927, that is on tap for a Phase 2 in ...

Endpoints News announces URL change from endpts.com to endpoints.news effective June 1, 2025, with legacy redirects planned ...